Drug Profile
PHA 793887
Alternative Names: PHA-793887Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nerviano Medical Sciences
- Class Antineoplastics; Pyrazoles; Pyrroles
- Mechanism of Action Cyclin-dependent kinase inhibitors; Glycogen synthase kinase 3 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Italy
- 10 Jul 2009 Phase-I clinical trials in Solid tumours in Italy (unspecified route)